Large gold nanoparticle release assay for attomolar detection of miRNA related to myelodysplastic neoplasms
Language English Country Netherlands Media print-electronic
Document type Journal Article
PubMed
40199123
DOI
10.1016/j.talanta.2025.128037
PII: S0039-9140(25)00527-2
Knihovny.cz E-resources
- Keywords
- Large gold nanoparticles, Myelodysplastic neoplasms, Nanoparticle release assay, Surface plasmon resonance, miRNA detection,
- MeSH
- Biosensing Techniques methods MeSH
- Metal Nanoparticles * chemistry MeSH
- Humans MeSH
- Limit of Detection MeSH
- MicroRNAs * blood genetics MeSH
- Myelodysplastic Syndromes * blood genetics diagnosis MeSH
- Biomarkers, Tumor blood MeSH
- Oligonucleotides chemistry MeSH
- Surface Plasmon Resonance MeSH
- Gold * chemistry MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- MicroRNAs * MeSH
- MIRN451 microRNA, human MeSH Browser
- Biomarkers, Tumor MeSH
- Oligonucleotides MeSH
- Gold * MeSH
MicroRNAs (miRNAs) hold potential as biomarkers for numerous cancer types, including myelodysplastic neoplasms (MDS). Here, we present a highly sensitive assay based on the oligonucleotide-triggered release of gold nanoparticles (AuNPs) for the detection of hsa-miR-451a with a surface plasmon resonance biosensor. The performance of the assay is in large part determined by the size and functional coating of AuNPs. Therefore, we investigate AuNPs in a size range from 43 to 170 nm, functionalized with thiol- or biotin-terminated oligonucleotides (AuNPsSdT or AuNPsBdT). Our study reveals that 103 nm AuNPsSdT are the best option to improve the assay performance due to their high colloidal stability, a release efficiency exceeding 90%, and a sensor response enhancement factor exceeding 105. We demonstrate that in conjunction with 103 nm AuNPsSdT, the AuNP release assay can detect hsa-miR-451a at levels down to 40 aM and quantify hsa-miR-451a physiological levels in human blood plasma. Moreover, we use the assay to demonstrate a significant down-regulation of hsa-miR-451a in blood plasma of MDS patients compared to healthy individuals, suggesting the potential relevance of hsa-miR-451a as a prospective MDS biomarker.
References provided by Crossref.org